Vanguard Group Inc. increased its holdings in shares of Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 13.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 2,011,705 shares of the company's stock after acquiring an additional 231,303 shares during the period. Vanguard Group Inc. owned about 5.13% of Cardlytics worth $33,193,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of CDLX. Deutsche Bank AG raised its position in Cardlytics by 5.0% during the 3rd quarter. Deutsche Bank AG now owns 43,992 shares of the company's stock valued at $726,000 after purchasing an additional 2,093 shares in the last quarter. Comerica Bank bought a new stake in Cardlytics during the 3rd quarter valued at $40,000. Tudor Investment Corp Et Al bought a new stake in Cardlytics during the 3rd quarter valued at $1,554,000. Gotham Asset Management LLC bought a new stake in Cardlytics during the 3rd quarter valued at $247,000. Finally, Tower Research Capital LLC TRC raised its position in Cardlytics by 186.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,137 shares of the company's stock valued at $35,000 after purchasing an additional 1,391 shares in the last quarter. 68.10% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, COO Amit Gupta sold 72,658 shares of the business's stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $6.10, for a total transaction of $443,213.80. Following the transaction, the chief operating officer now directly owns 102,342 shares in the company, valued at approximately $624,286.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Cardlytics news, insider Nicholas Hollmeyer Lynton sold 12,460 shares of Cardlytics stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $13.69, for a total transaction of $170,577.40. Following the completion of the sale, the insider now owns 71,355 shares of the company's stock, valued at approximately $976,849.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Amit Gupta sold 72,658 shares of Cardlytics stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $6.10, for a total value of $443,213.80. Following the sale, the chief operating officer now directly owns 102,342 shares of the company's stock, valued at approximately $624,286.20. The disclosure for this sale can be found here. Insiders have sold a total of 85,272 shares of company stock worth $616,010 in the last ninety days. 0.78% of the stock is owned by insiders.
Cardlytics Stock Down 5.6 %
Shares of NASDAQ:CDLX traded down $0.81 on Friday, reaching $13.57. The company had a trading volume of 644,477 shares, compared to its average volume of 1,614,628. Cardlytics, Inc. has a 52-week low of $4.94 and a 52-week high of $20.52. The firm's 50 day simple moving average is $10.26 and its 200-day simple moving average is $9.79. The firm has a market capitalization of $598.57 million, a PE ratio of -3.92 and a beta of 1.44. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 1.91.
Cardlytics (NASDAQ:CDLX - Get Free Report) last announced its earnings results on Thursday, March 14th. The company reported ($0.14) earnings per share for the quarter. Cardlytics had a negative return on equity of 25.38% and a negative net margin of 43.56%. The business had revenue of $89.17 million for the quarter.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Craig Hallum raised Cardlytics from a "hold" rating to a "buy" rating and lifted their target price for the company from $10.00 to $18.00 in a research report on Friday, March 15th. Lake Street Capital lifted their target price on Cardlytics from $13.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, March 15th. Finally, Needham & Company LLC lifted their price target on Cardlytics from $15.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $13.60.
Get Our Latest Report on CDLX
About Cardlytics
(
Free Report)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
See Also
Before you consider Cardlytics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.
While Cardlytics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
